Literature DB >> 12500881

How effectively do managed care organizations influence prescribing and dispensing decisions?

Norman V Carroll1.   

Abstract

OBJECTIVE: To examine the extent to which managed care organizations (MCOs) use formularies, therapeutic interchange, and prior approval and to determine how effectively these tools influence prescribing and dispensing decisions. RESEARCH
DESIGN: Literature review. PATIENTS AND METHODS: Studies relating to effectiveness were identified through a comprehensive literature review using the MEDLINE and International Pharmaceutical Abstracts databases. Only peer-reviewed studies done in outpatient settings were included. Studies measuring extent of use were taken primarily from published and widely available marketing research reports.
RESULTS: Closed formularies were found to be effective in decreasing the utilization, but not necessarily the cost, of prescription drugs. Just under half of health maintenance organizations (HMOs) and 10% of employer-sponsored health plans use closed formularies. Prior approval programs have been shown to reduce use of target drugs and drug costs in a small number of drug classes. Nearly all HMOs and most employer-sponsored health plans use prior approval programs. How extensively the programs are used is not reported. About half of HMOs and employer-sponsored health plans use therapeutic interchange. Voluntary programs have been shown to be successful in staff-model HMOs. Mandatory, but not voluntary, programs have been shown to be successful in independent practice association-model HMOs.
CONCLUSION: The literature indicates that most MCOs have had limited success using formularies, therapeutic interchange, and prior approval to influence prescribing and dispensing decisions. Although these tools have been effective in some situations, their impact has been limited by their low rate of utilization.

Entities:  

Mesh:

Year:  2002        PMID: 12500881

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  8 in total

Review 1.  Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

Authors:  Jaume Puig-Junoy; Iván Moreno-Torres
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 2.  The relevance of systematic reviews on pharmaceutical policy to low- and middle-income countries.

Authors:  Andrew Lofts Gray; Fatima Suleman
Journal:  Int J Clin Pharm       Date:  2015-07-17

3.  Overprescribing of lipid lowering agents.

Authors:  M A Smith; E D Cox; J M Bartell
Journal:  Qual Saf Health Care       Date:  2006-08

4.  Prescribing patterns for Alzheimer disease: survey of Canadian family physicians.

Authors:  Melinda Hillmer; Murray Krahn; Michael Hillmer; Pauline Pariser; Gary Naglie
Journal:  Can Fam Physician       Date:  2006-02       Impact factor: 3.275

5.  Impact of Medicaid preferred drug lists on therapeutic adherence.

Authors:  David B Ridley; Kirsten J Axelsen
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic.

Authors:  James L Raper; James H Willig; Hui-Yi Lin; Jeroan J Allison; M Bennet Broner; Michael J Mugavero; Michael S Saag
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

7.  ePrescribing: Reducing Costs through In-Class Therapeutic Interchange.

Authors:  Shane P Stenner; Rohini Chakravarthy; Kevin B Johnson; William L Miller; Julie Olson; Marleen Wickizer; Nate N Johnson; Rick Ohmer; David R Uskavitch; Gordon R Bernard; Erin B Neal; Christoph U Lehmann
Journal:  Appl Clin Inform       Date:  2016-12-14       Impact factor: 2.342

Review 8.  Preferred drug lists: potential impact on healthcare economics.

Authors:  Kimberly Ovsag; Sabrina Hydery; Shaker A Mousa
Journal:  Vasc Health Risk Manag       Date:  2008
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.